Randomized trial · people

Pramlintide: 3.7% placebo-corrected weight loss at 16 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this short trial, pramlintide alone, without a lifestyle program, led to modest weight loss beyond placebo in people with obesity, and the loss did not depend on having nausea.

Kind
Randomized trial
Studied in
People
Number studied
204
Published
2007
Journal
J Clin Endocrinol Metab

What they tested

The team tested whether pramlintide, at doses higher than earlier studies used, lowers body weight in people with obesity, and how safe and tolerable it is.

How the study was done

A phase 2 randomized, double-blind, placebo-controlled trial at several centers in 204 adults with obesity, with or without type 2 diabetes, none using insulin. For 16 weeks they injected pramlintide or placebo (a dummy shot) under the skin three times a day before meals, with the dose stepped up to as much as 240 microg, and no diet or exercise program added.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking pramlintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

People who finished 16 weeks on pramlintide lost 3.7 ± 0.5% of body weight (3.6 ± 0.6 kg) and 3.6 ± 1.1 cm of waist size beyond what the placebo group lost. About 31% of the pramlintide group lost at least 5% of their weight, compared with 2% on placebo. In all, 88% reached the 240 microg dose, and dropout was 29% on pramlintide vs 25% on placebo. The most common side effect was mild nausea that passed, and weight loss was similar in people with nausea (3.9 ± 0.5%) and without it (3.6 ± 0.5%).

What it doesn’t show

This was a short, 16-week phase 2 trial, and the weight results are for people who completed it, while about a quarter or more of each group dropped out. It doesn't show whether the weight loss lasts or grows over a longer time.

The paper

Aronne et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007.

The compound

More studies on Pramlintide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking pramlintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo